Market Trends of Hyperhidrosis Treatment Industry
Botulin Toxin A is Expected to Hold the Largest Market Share Over the Forecast Period
Botulinum toxin treatment type A is a safe and effective treatment for focal hyperhidrosis that lasts longer than topical treatments and does not require invasive surgical procedures. Botulinum toxin injections are most commonly used as axillary hyperhidrosis treatment but can also serve as palmar hyperhidrosis treatment and plantar hyperhidrosis treatment. Botulinum toxin's effects last six to nine months on average, and treatment is linked to a high satisfaction rate among patients.
AbbVie Inc. owns BOTOX, which is the most researched botulinum toxin in the world. BOTOX has been approved for the treatment of excessive sweating in the underarms in at least 20 countries. It can also be used off-label to treat sweating in the face, feet, and hands. In April 2021, Aquavit Holdings LLC announced that it acquired an exclusive license to register, market, and commercialize a botulinum toxin (DTX-021) in the United States and Canada. Excessive sweating of the armpits, hands, feet, head, and face (craniofacial) and other relatively small body areas (like under the breasts) can be treated with botulinum toxin A as per the article published by the International Hyperhidrosis Society in October 2020. BOTOX has been shown to reduce sweating by 82.0% to 87.0% when used to treat excessive sweating under the arms. The effects begin to show up two to four days after treatment, with the full effects usually appearing within two weeks. Dryness lasts four to 12 months on average, but some studies have found that it can last up to 14 months.
Various studies have demonstrated its efficacy in reducing anxiety as well. For instance, according to a study published in the journal Scientific Reports in 2021, people who received BOTOX injections at four different sites reported significantly fewer signs of anxiety than those who received different treatments for the same conditions. The risk of anxiety was found to be reduced by 22.0% to 72.0% in BOTOX patients. Hence, the effectiveness of botulinum toxin type A in hyperhidrosis treatment and its long-lasting effect is driving the market's growth.
North America is Expected to Hold the Largest Market Share Over the Forecast Period
North America is expected to dominate the overall hyperhidrosis treatment market throughout the forecast period. The growth is owing to factors such as the increasing burden of primary hyperhidrosis, cancer, and cardiovascular disorders, increases in secondary hyperhidrosis, technological advancements in hyperhidrosis medication, and the presence of key market players in the region.
The high prevalence of primary and secondary hyperhidrosis will increase the adoption of hyperhidrosis treatments in the region. According to the NCBI research paper published in October 2022, approximately 2.8% of the US population suffers from hyperhidrosis, which is common in patients between 20 to 60 years of age. The high prevalence has increased the adoption of various treatments, including over-the-counter aluminum chloride hexahydrate 20.0% and prescription antiperspirants in the region. Such prevalence will increase the demand for product consumption, thereby increasing the hyperhidrosis treatment market size.
Key product launches, high concentration of market players or manufacturer's presence, acquisition and partnerships among major players, and increasing research and development activities for hyperhidrosis treatments in the United States will lead to higher adoption of these products. For instance, in April 2021, Fortress Biotech, a partner company of Journey Medicals, entered into a definitive agreement to acquire Qbrexza (glycopyrronium), an anticholinergic medication in the United States from Dermira, a wholly-owned subsidiary of Eli Lilly. Thus, owing to the above-mentioned factors, the market is expected to witness considerable growth over the forecast period.
